FP7 Health presentation Jan' 08

1
Trends and Future directions for Health research
in FP7
Stéphane Hogan Head of unit Horizontal Aspects
and Coordination Directorate Health DG Research
European Commission
IGBF conference 2-3 February 2008
2
Framework Programme

• AIMS
• support to EU competitiveness by promoting
  research and innovation
• MEANS
• Funding collaborative research Cooperation
  programme
• Coordinating national activities, eg ERA-NETs
• CHARACTERISTICS
• selects and supports only the very best projects
  through a fair and transparent evaluation system
• can involve partners from all of Europe the
  World.

3
FP7 budget (2007-2013) 55 billion
4
Cooperation programmethematic areas (32.4
billion)
5
Cooperation Collaborative research in FP7

• Thematic Priorities
• Health 6.1
• Food, agriculture, fisheries and
  biotechnology 1.9
• Information and communication technologies 9.1
• Nanosciences, nanotechnologies, materials and
  new production technologies 3.5
• Energy 2.3
• Environment (including climate change) 1.9
• Transport (including aeronautics) 4.2
• Socio-economic sciences and the humanities 0.6
• Security 10. Space 2.8
• Total for collaborative research
  32.4 billion

6
Collaborative research in the Health theme
pillar 3 Optimising the delivery of health
care
pillar 2 Translating research for human health
pillar 1 Biotechnology, generic tools
technologies for health
cross-cutting issues child health, the health
of ageing population gender-related health
issues
pillar 4 Other actions across the theme
7
Collaborative researchin the Health theme

• 1 Biotechnology, generic tools and technologies
• High-throughput research enhancing data
  generation, standardisation, acquisition
  analysis
• Detection, diagnosis and monitoring with
  emphasis on non-invasive or minimally invasive
  approaches
• Predicting suitability, safety and efficacy of
  therapies develop and validate parameters, tools,
  methods and standards and alternatives to animal
  testing (mainly through IMI)
• Innovative therapeutic approaches and
  interventionsgene and cell therapy, regenerative
  medicine, immunotherapy and vaccines.

8
Collaborative researchon the Health theme

• 2 Translating research for human health
• Integrating biological data and processes
  large-scale data gathering, systems biology
• Research on the brain and related diseases,
  human development and ageing
• Translational research in major infectious
  diseasesto confront major threats to public
  health antimicrobial drug resistance, HIV/AIDS,
  malaria and TB, emerging epidemics, neglected
  infectious diseases
• Translational research in other major diseases
  cancer, cardiovascular disease, diabetes and
  obesity, rare diseases, and other chronic
  diseases

9
Collaborative researchin the Health theme

• 3 Optimising the delivery of health care to
  citizens
• Translating clinical research into clinical
  practice patient safety, better use of
  medicines, pharmacovigilance, etc.
• Quality, efficiency and solidarity of health care
  systems organisational and financial aspects,
  health systems, etc.
• Enhanced health promotion and disease prevention
  providing evidence of best public health measures
  life styles, interventions, special focus on
  mental health, etc.

• 4 Other actions across the theme
• Coordination and Support Actions across the Theme
• Responding to EU policy needs

10
Trends in from FP6 to FP7Collaborative research
in Health

• Trends from FP6 to FP7
• Continuity building on FP6
• Broader scope.
• less focus on genomics
• more emphasis on translational research
• new areas emerging epidemics, obesity, chronic
  diseases, biomedical technology engineering.
  
• health policy driven research strongly reinforced.

11
Trends SMEs participation International
Cooperation

• Renewed emphasis and new measures for
• SMEs
• Participation encouraged in all areas
• Special topics for SMEs
• Support actions
• more favourable conditions (75 of costs
  covered)
• International Cooperation
• Participation possible in all areas
• Special International Cooperation Actions (SICA)
• Coordination or Support actions
• new mechanisms coordinated programmes and topics

12
Enhanced efforts to involve research-intensive
SMEs

• Medium/long term vision 7-year programme
• Significant commitment for SMEs (15) (gt900m
  for Health)
• Improved conditions in FP7
• Strong support up to 75 of total RD costs for
  research and up to 100 for management and
  training
• Better protection IPR rules more attentive to
  SMEs needs
• Administrative simplification reduced need for
  financial checks and bank guarantees

13
International participation in FP7 - Health
research

• Short term opportunities
• All areas open for international collaboration
• Specific opportunities in ongoing calls(SICA and
  other topics)
• Medium term opportunities
• Identify promote specific areas for
  cooperationthrough coordinated
• Coordination of programmes
• eg Mouse genomics with NIH and Genome Canada
• Coordination of topics (in next call)

14
Supply Demand in FP6 to FP7
15
Annual calls coverage of Specific Programme

• Each annual call for proposals will not cover
  whole SP
• 1st two calls (budget 2007 2008) covered entire
  Specific programme (SP), but some areas closed in
  each call.
• eg
• Optimising the delivery of health care
  closed in 1st call
• Predicting suitability, safety efficacy of
  therapies and Human Development and Ageing
  closed in 2nd call
• same approach proposed for 3rd 4th calls
• i.e. some areas will be closed in each call.

16
Basic principles unchanged for calls and
evaluations

• annual calls competitive basis peer review
• 3 criteria
• Science Technology excellence
• Implementation Management
• Potential Impact
• evaluation by panels of independent experts
• overseen by Independent Observers

17
First calls in Health themeTrends from 1st call

• 1st call deadline closed 19 April 2007
• budget 635 million
• 914 proposals received (21 ineligible)
• 893 proposals evaluated
• 152 proposals short-listed for funding 17 of
  proposals evaluated
• average grant per participant 412,000
• SMEs in 120/152 projects (79)
• 299 SMEs out of 1540 participants (19)
• SMEs will receive 100 million (15)

18
First calls in Health theme Trends from 2nd call

• 2nd call deadline closed 18 September 2007
• budget 549 million
• 902 proposals received (37 ineligible)
• 865 proposals evaluated
• 167 proposals to be short-listed 19 of
  proposals evaluated
• average grant per participant 334,000
• SMEs in 128/167 projects (77)
• 353 SMEs out of 1697 participants (21)
• SMEs will receive 108 million (18)

19
Eligibility and quality issues

• Requirements for eligibility
• meet the deadline with complete proposal
• have the minimum number of partners
• respect ceilings for max. EU contribution per
  project
• Quality is a prerequisite for success
• page number limitations for proposals (new in
  FP7)
• added requirements for information on ethics
  issues

20
Ineligibility and quality issues

• Ineligibility cases in 1st call 21/914
• ceilings not respected 11
• minimum n partners 5
• withdrawn, test or incomplete 5
• Ineligibility cases in the 2nd call 37/902
• ceilings not respected 23
• minimum n partners 11
• withdrawn 1
• out of scope 3

21
FP7 calls for proposals for the Health theme

• IMI call to be published in 2008
• expected budget 125 million (2008 budget)
• deadline ?
• 3rd call to be published July 2008 (2009
  budget)
• expected budget 600 million
• expected deadline Oct./Nov. 2008
• 4th call published July 2009 (2010 budget)
• revised budget 600 million
• deadline Oct./Nov. 2009

22
Key messages for success in FP7

• Competition is tough only the best projects
  get funded
• The proposal must be in scope with the
  topic/work programme
• The consortium of partners must be excellent
  and appropriate for the task
• The proposal must address all 3 criteria
• Convince the evaluators (dont rely on
  reputation)
• and, of course, respect the basic rules.

23
The Health Directorate
Director (acting) Dr. Manuel Hallen Medical
and Public Health Research unit (F2) Head of
unit Dr. Manuel Hallen (manuel.hallen_at_ec.europa.e
u) Deputy Head of Unit Dr. Maria Vidal
(maria-jose.vidal-ragout_at_ec.europa.eu) Head of
sector Public Health K. McCarthy
(kevin.mccarthy_at_ec.europa.eu) Infectious Diseases
unit (F3) Head of unit Dr. Alain Vanvossel
(alain.vanvossel_at_ec.europa.eu) Deputy Head of
unit Dr. Anna Lönnroth (anna.lonnroth_at_ec.europa.e
u) Head of IMI sector Dr. Irene Norstedt
(irene.norstedt_at_ec.europa.eu) Genomics and
Systems Biology unit (F4) Head of unit Patrik
Kolar (patrik.kolar_at_ec.europa.eu) Deputy Head of
unit Dr. B. Mulligan (bernard.mulligan_at_ec.europa.
eu) Health Biotechnology unit (F5) Head of unit
Dr. Arnd Hoeveler (arnd.hoeveler_at_ec.europa.eu)
Coordination unit (F1) Head of unit Stéphane
Hogan (stephane.hogan_at_ec.europa.eu)
Admin. Finance unit (F6)Head of unit Giorgios
Zisimatos(georgios.zisimatos_at_ec.europa.eu)
24
Contacts Information
Consult the web page for Health
http//cordis.europa.eu/fp7/health/including
NCPs, Ethics, registration as an Expert
International Cooperation Dr. Indridi
BenediktssonTel. 32 2 299 3137 Email
indridi.benediktsson_at_ec.europa.eu SME
participation Dr. Ludovica SerafiniTel. 32 2
295 6759 Email ludovica.serafini_at_ec.europa.eu E
thical issues Dr. Joana NamoradoTel. 32 2 298
5466 Email joana.namorado_at_ec.europa.eu Innovati
ve Medicines Initiative (IMI) Dr. Irene
NorstedtTel. 32 2 296 9527 Email
irene.norstedt_at_ec.europa.eu